MedTrace Logo

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

NCT04170829 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-12-01

No results posted yet for this study

Summary

A phase Ib study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers

Conditions

  • Middle East Respiratory Syndrome Coronavirus

Interventions

BIOLOGICAL

ChAdOx1 MERS

a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • King Abdullah International Medical Research Center

    lead OTHER

Principal Investigators

  • Mohammad Bosaeed, MD · Ministry of National Guard-Health Affairs (MNGHA)

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2020-11-26
Completion
2020-11-26

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170829 on ClinicalTrials.gov